Serentis Starts Phase II Clinical Trial in Pruritus of Skin Disease

Published: Mar 04, 2009

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Serentis, a privately owned biopharmaceutical company, announced today that it has started a phase II clinical trial in pruritus associated with atopic dermatitis (AD), a type of eczema. Pruritus, more commonly known as itch, is a major symptom of AD. The lack of effective treatments of pruritus has been identified as a major unmet medical need for patients with AD.

Back to news